Harmonizing light transmission aggregometry in the Netherlands by implementation of the SSC-ISTH guideline.

Light transmission aggregometry platelet aggregation platelet disorders platelet function platelets standardization

Journal

Platelets
ISSN: 1369-1635
Titre abrégé: Platelets
Pays: England
ID NLM: 9208117

Informations de publication

Date de publication:
19 May 2021
Historique:
pubmed: 12 6 2020
medline: 5 1 2022
entrez: 12 6 2020
Statut: ppublish

Résumé

Light transmission aggregometry (LTA) is considered the gold standard method for evaluation of platelet function. However, there are a lot of variation in protocols (pre-analytical procedures and agonist concentrations) and results. The aim of our study was to establish a national LTA protocol, to investigate the effect of standardization and to define national reference values for LTA. The SSC guideline was used as base for a national procedure. Almost all recommendations of the SSC were followed e.g. no adjustment of PRP, citrate concentration of 109 mM, 21 needle gauge, fasting, resting time for whole blood and PRP, centrifugation time, speed and agonists concentrations. LTA of healthy volunteers was measured in a total of 16 hospitals with 5 hospitals before and after standardization. Results of more than 120 healthy volunteers (maximum aggregation %) were collected, with participating laboratories using 4 different analyzers with different reagents. Use of low agonist concentrations showed high variation before and after standardization, with the exception of collagen. For most high agonist concentrations (ADP, collagen, ristocetin, epinephrine and arachidonic acid) variability in healthy subjects decreased after standardization. We can conclude that a standardized Dutch protocol for LTA, based on the SSC guideline, does not result in smaller variability in healthy volunteers for all agonist concentrations.

Identifiants

pubmed: 32522065
doi: 10.1080/09537104.2020.1771549
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

516-523

Auteurs

I C A Munnix (ICA)

Department of Clinical Chemistry, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands.

R Van Oerle (R)

Central Diagnostic Laboratory, Maastricht University Medical Centre +, Maastricht, The Netherlands.

P Verhezen (P)

Central Diagnostic Laboratory, Maastricht University Medical Centre +, Maastricht, The Netherlands.

P Kuijper (P)

Clinical Laboratory, Maxima Medical Centre, Veldhoven, The Netherlands.

C M Hackeng (CM)

Department of Clinical Chemistry, St. Antonius Hospital, Nieuwegein, The Netherlands.

H I J Hopman-Kerkhoff (HIJ)

Department of Hematology, AmsterdamUMC Location VUMC, Amsterdam, The Netherlands.

F Hudig (F)

LabWest, Haga Teaching Hospital, The Hague, The Netherlands.

D Van De Kerkhof (D)

Clinical Laboratory, Catharina Hospital, Eindhoven, The Netherlands.

A Leyte (A)

Department of Clinical Chemistry, OLVG Laboratoria BV, Amsterdam, The Netherlands.

M P M De Maat (MPM)

Department of Hematology, Erasmus University Medical Centre Rotterdam, Rotterdam, The Netherlands.

R F M Oude Elferink (RFM)

Departmentof Clinical Chemistry, Certe, Groningen, The Netherlands.

J Ruinemans-Koerts (J)

Department of Clinical Chemistry and Haematology, Rijnstate Hospital, Arnhem, The Netherlands.

M Schoorl (M)

Department of Clinical Chemistry, Haematology & Immunology,Northwest Clinics, Alkmaar, The Netherlands.

J Slomp (J)

Department of Clinical Chemistry, Medlon, Location Medisch Spectrum Twente, Enschede, The Netherlands.

H Soons (H)

Department of Clinical Chemistry, St. Anna Hospital, Geldrop, The Netherlands.

A Stroobants (A)

Department of Clinical Chemistry, AmsterdamUMC Location AMC, Amsterdam, The Netherlands.

E Van Wijk (E)

Department of Clinical Chemistry, St. Elisabeth Hospital, Tilburg, The Netherlands.

Y M C Henskens (YMC)

Central Diagnostic Laboratory, Maastricht University Medical Centre +, Maastricht, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH